OACC vs IQV vs CRL vs ICLR

For growth investors, IQVIA Holdings Inc.

(IQV) is the stronger pick with 5. 9% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). ICON Public Limited Company (ICLR) offers the better valuation at 13. 1x trailing P/E (10. 5x forward), making it the more compelling value choice. Analysts rate IQVIA Holdings Inc. (IQV) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ICON Public Limited Company (ICLR) is the cheapest at 13.

1x versus Oaktree Acquisition Corp. III Life Sciences at 195. 8x. On forward P/E, ICON Public Limited Company is actually cheaper at 10. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus ICON Public Limited Company's 1. 50x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Oaktree Acquisition Corp.

III Life Sciences (OACC) delivered a total return of +6. 1%, compared to -46. 9% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: IQV returned +166. 5% versus OACC's +6. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Oaktree Acquisition Corp.

III Life Sciences (OACC) is the lower-risk stock at 0. 08β versus ICON Public Limited Company's 1. 60β — meaning ICLR is approximately 1876% more volatile than OACC relative to the S&P 500. On balance sheet safety, Oaktree Acquisition Corp. III Life Sciences (OACC) carries a lower debt/equity ratio of 0% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IQVIA Holdings Inc.

(IQV) is pulling ahead at 5. 9% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: ICON Public Limited Company grew EPS 28. 8% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, ICLR leads at 14. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ICON Public Limited Company (ICLR) is the more profitable company, earning 9.

6% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 9. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus 0. 0% for OACC. At the gross margin level — before operating expenses — CRL leads at 30. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus ICON Public Limited Company's 1. 50x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, ICON Public Limited Company (ICLR) trades at 10. 5x forward P/E versus 16. 4x for Charles River Laboratories International, Inc. — 5. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IQV: 26. 3% to $225. 63.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Oaktree Acquisition Corp.

III Life Sciences (OACC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 08)). ICON Public Limited Company (ICLR) carries a higher beta of 1. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OACC: +6. 1%, ICLR: +91. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (OACC (Financial Services) and IQV (Healthcare) and CRL (Healthcare) and ICLR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: OACC is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock; CRL is a small-cap quality compounder stock; ICLR is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.